About Takeda Pharmaceutical Company Limited
https://www.takeda.comTakeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience.
CEO
Christophe Weber
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : B
Price Target
Institutional Ownership
CAPITAL RESEARCH GLOBAL INVESTORS
Shares:13.4M
Value:$220.77M
MORGAN STANLEY
Shares:7.69M
Value:$126.66M
TIAA CREF INVESTMENT MANAGEMENT LLC
Shares:6.56M
Value:$107.97M
Summary
Showing Top 3 of 427
About Takeda Pharmaceutical Company Limited
https://www.takeda.comTakeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $1.11T ▲ | $663.74B ▲ | $-11.8B ▼ | -1.06% ▼ | $-3.74 ▼ | $316.47B ▼ |
| Q1-2025 | $1.11T ▲ | $537.44B ▼ | $124.24B ▲ | 11.23% ▲ | $39.7 ▲ | $439.42B ▲ |
| Q4-2024 | $1.05T ▼ | $746.2B ▲ | $-103.2B ▼ | -9.8% ▼ | $-32.62 ▼ | $181.27B ▼ |
| Q3-2024 | $1.14T ▼ | $660.31B ▲ | $23.79B ▼ | 2.08% ▼ | $7.51 ▼ | $193.01B ▼ |
| Q2-2024 | $1.18T | $597.48B | $92.05B | 7.83% | $29.07 | $380.28B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $739.68B ▲ | $14.47T ▲ | $7.34T ▲ | $7.13T ▲ |
| Q1-2025 | $419.18B ▲ | $14T ▼ | $7.14T ▼ | $6.87T ▼ |
| Q4-2024 | $405.59B ▼ | $14.25T ▼ | $7.31T ▼ | $6.94T ▼ |
| Q3-2024 | $526.75B ▼ | $15.11T ▲ | $7.69T ▲ | $7.42T ▲ |
| Q2-2024 | $906.22B | $14.57T | $7.65T | $6.92T |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-11.73B ▼ | $378.23B ▲ | $-48.13B ▼ | $-11.98B ▲ | $331.48B ▲ | $325.4B ▲ |
| Q1-2025 | $124.28B ▲ | $215.42B ▼ | $-33.19B ▼ | $-214.9B ▲ | $-35.1B ▲ | $140.35B ▼ |
| Q4-2024 | $-103.2B ▼ | $222.16B ▼ | $-19.68B ▲ | $-301.79B ▲ | $-109.01B ▲ | $173.37B ▼ |
| Q3-2024 | $23.79B ▼ | $383.76B ▲ | $-115.56B ▼ | $-655.97B ▼ | $-364.89B ▼ | $338.67B ▲ |
| Q2-2024 | $92.05B | $280.96B | $-75.13B | $-110.05B | $54B | $231.49B |
CEO
Christophe Weber
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 15
Ratings Snapshot
Rating : B
Price Target
Institutional Ownership
CAPITAL RESEARCH GLOBAL INVESTORS
Shares:13.4M
Value:$220.77M
MORGAN STANLEY
Shares:7.69M
Value:$126.66M
TIAA CREF INVESTMENT MANAGEMENT LLC
Shares:6.56M
Value:$107.97M
Summary
Showing Top 3 of 427